
Hologic (HOLX) Stock Forecast & Price Target
Hologic (HOLX) Analyst Ratings
Bulls say
Hologic is positioned for positive financial performance due to strong anticipated organic revenue growth of 5-7%, driven by robust procedure volume increases, impactful new product launches, and strategic tuck-in acquisitions across its Diagnostics, Breast Health, and GYN Surgical segments. The company's bull case scenario envisions revenue growth accelerating into the high single digits (7-9%) and margin expansion of over 50 basis points, contributing to projected earnings growth between 8-12%. Furthermore, Hologic's solid balance sheet and limited leverage support its potential for improved operating efficiencies and business performance, enhancing the overall investment outlook.
Bears say
Hologic faces a negative outlook primarily due to expected revenue growth slowing to low-single digits (1-4%), driven by weakness in its key segments of Diagnostics and Breast Health, which are crucial for overall performance. The company has seen disappointing returns over the past three to five years and struggles with re-accelerating growth post-COVID amid a challenging economic environment that could further reduce demand for its products and services. Additionally, risks such as a slowdown in hospital capital spending, potential market share loss, and integration challenges from recent acquisitions compound the uncertainty around Hologic's future profitability and operational margins.
This aggregate rating is based on analysts' research of Hologic and is not a guaranteed prediction by Public.com or investment advice.
Hologic (HOLX) Analyst Forecast & Price Prediction
Start investing in Hologic (HOLX)
Order type
Buy in
Order amount
Est. shares
0 shares